Latest from Moffitt

David Sallman, MD, assistant member, Moffitt Cancer Center, discusses the combination of APR-246 and azacitidine as a treatment for patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.
Hatem Soliman, MD, medical oncologist, The Center for Women’s Oncology, Moffitt Cancer Center, discusses the use of combination therapies in the treatment of patients with breast cancer.
Hung T. Khong, MD, discusses the benefits of neoadjuvant endocrine therapy and addresses the use of adjuvant endocrine therapy in ER-positive breast cancer.
Hatem Soliman, MD, discusses the potential role of immunotherapy in triple-negative breast cancer.
Frederick L. Locke, MD, discusses the ongoing ZUMA-2 trial investigating axi-cel for patients with mantle cell lymphoma. 
Hung T. Khong, MD, medical oncologist, Moffitt Cancer Center, discusses the use of neoadjuvant endocrine therapy.
Heather S. Han, MD, research director, medical oncologist, Department of Breast Oncology, Moffitt Cancer Center, discusses the differences between CDK 4/6 inhibitors, and their efficacy as both single- and combination agents.
Jonathan R. Strosberg, MD, discusses ongoing advances and challenges in the treatment of patients with NETs.
Publication Bottom Border
Border Publication
x